B. Riley Securities Maintains Buy on TG Therapeutics, Lowers Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Mayank Mamtani maintains a 'Buy' rating on TG Therapeutics (NASDAQ:TGTX), but has lowered the price target from $42 to $32.

August 04, 2023 | 11:41 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TG Therapeutics' price target has been lowered from $42 to $32 by B. Riley Securities, though the 'Buy' rating is maintained.
The lowering of the price target by B. Riley Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could offset some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100